Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
Arthritis and Rheumatism|May 28, 2010
Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffoldMaria-Concetta Veri, Stephen Burke, Ling Huang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2016
MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell MalignanciesLiqin Liu, Chia-Ying K Lam, Vatana Long, et al.Blood|February 9, 2011
Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphomaPaul A Moore, Wenjun Zhang, G Jonah Rainey, et al.Molecular Cancer Therapeutics|October 30, 2025
Preclinical development of MGC028, an ADAM9-targeted, glycan-linked, exatecan-based antibody-drug conjugate for the treatment of solid cancersJuniper A Scribner, Jennifer G Brown, Thomas Son, et al.Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract|October 8, 2017
The Effects of Travel Burden on Outcomes After Resection of Extrahepatic Biliary Malignancies: Results from the US Extrahepatic Biliary ConsortiumSean C O'Connor, Harveshp Mogal, Gregory Russell, et al.Journal of Surgical Oncology|December 6, 2017
Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survivalXu-Feng Zhang, Eliza W Beal, Katiuscha Merath, et al.HPB : the Official Journal of the International Hepato Pancreato Biliary Association|September 30, 2016
Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy ConsortiumEliza W Beal, Lai Wei, Cecilia G Ethun, et al.Annals of Surgical Oncology|February 23, 2018
The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar CholangiocarcinomaXu-Feng Zhang, Malcolm H Squires, Fabio Bagante, et al.World Journal of Surgery|February 7, 2018
Defining Early Recurrence of Hilar Cholangiocarcinoma After Curative-intent Surgery: A Multi-institutional Study from the US Extrahepatic Biliary Malignancy ConsortiumXu-Feng Zhang, Eliza W Beal, Jeffery Chakedis, et al.Annals of Surgical Oncology|June 6, 2018
Role of Additional Organ Resection in Adrenocortical Carcinoma: Analysis of 167 Patients from the U.S. Adrenocortical Carcinoma DatabasePaula Marincola Smith, Colleen M Kiernan, Thuy B Tran, et al.Pageof 3